CTLT - Catalent, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD

Catalent, Inc.

14 Schoolhouse Road
Somerset, NJ 08873
United States

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees13,000

Key Executives

NameTitlePayExercisedYear Born
Mr. John R. ChiminskiChairman & CEO2.59M6.95M1964
Mr. Alessandro MaselliPres & COO1.43MN/A1972
Mr. Wetteny N. JosephSr. VP & CFO936.22k335.73k1972
Mr. Steven L. FasmanSr. VP, Gen. Counsel & Corp. Sec.1.04MN/A1963
Mr. Peter L. BuzyPres of Gene Therapy535.1kN/A1960
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment engages in the drug substance development and manufacturing; drug product clinical and commercial manufacturing; and integrated clinical and commercial supply solutions for protein and gene therapy biologics and specialty small molecules through injection, inhalation, and ophthalmic routes. The Oral Drug Delivery segment formulates, develops, and manufactures technologies and related integrated solutions for a range of oral dose forms, including its proprietary fast-dissolve Zydis tablets and conventional tablets, capsules, and sachet products. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has an agreement with Cycle Pharmaceuticals Ltd. to develop formulations targeting rare disease patients. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.

Corporate Governance

Catalent, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 5. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 3; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.